세계의 유아성 경련 치료제 시장 규모, 점유율, 성장 분석, 치료제별, 유형별, 형태별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Infantile Spasms Therapeutics Market Size, Share, and Growth Analysis, By Treatment, By Type, By Dosage, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1734408
리서치사:SkyQuest
발행일:2025년 05월
페이지 정보:영문 191 Pages
라이선스 & 가격 (부가세 별도)
한글목차
유아성 경련 치료제 세계 시장 규모는 2023년 1억 4,000만 달러, 2024년 1억 4,924만 달러에서 2032년에는 2억 4,885만 달러로 성장하고, 예측 기간(2025-2032년)의 CAGR은 6.6%를 나타낼 전망입니다.
시장 개발 인사이트에 따르면, 영아 경련 치료제에 대한 세계 수요는 선진국과 신흥 시장 모두에서 유병률이 증가하고 있는 추세에 힘입어 성장하고 있습니다. 소아과 의사의 인식 개선과 연구개발에 대한 막대한 투자가 매출 성장을 견인하고 있으며, 약물 제제의 발전과 소아신경학 서비스의 확대가 이러한 치료법에 대한 접근성을 향상시키고 있습니다. 첨단 뇌파, MRI, 유전자 시퀀싱과 같은 혁신적인 도구가 조기 진단을 촉진하고 있습니다. 정부 의료 프로그램 및 비영리 단체의 지원으로 희귀 소아 신경질환에 대한 인식과 자금이 더욱 증가하고 있습니다. 그러나 높은 치료비, 숙련된 전문의 부족, 기존 치료제의 부작용 가능성, 후진국에서의 진단 부족 등의 문제는 향후 시장 매출에 걸림돌이 될 수 있습니다.
목차
서론
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter의 Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁 정도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
유아성 경련 치료제 시장 규모 : 치료제별&CAGR(2025-2032)
시장 개요
항경련제
코르티코스테로이드
기타
유아성 경련 치료제 시장 규모 : 유형별&CAGR(2025-2032)
시장 개요
비가바트린
부신피질 자극 호르몬
3상
유아성 경련 치료제 시장 규모 : 형태별&CAGR(2025-2032)
시장 개요
고체
액체
유아성 경련 치료제 시장 규모 : 투여 경로별&CAGR(2025-2032)
시장 개요
경구
비경구
기타
유아성 경련 치료제 시장 규모 : 최종사용자별&CAGR(2025-2032)
시장 개요
클리닉
병원
기타
유아성 경련 치료제 시장 규모 : 유통 채널별&CAGR(2025-2032)
시장 개요
병원 약국
소매 약국
온라인 약국
유아성 경련 치료제 시장 규모 : 지역별&CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
주요 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 상세
제품 포트폴리오 분석
기업 부문별 점유율 분석
매출 전년대비 비교(2022-2024년)
주요 기업 개요
Amneal Pharmaceuticals LLC(U.S.)
Cipla(India)
Endo, Inc.(U.S.)
H. Lundbeck A/S(Denmark)
Hetero(India)
Intas Pharmaceuticals Ltd.(India)
Jazz Pharmaceuticals, Inc.(Ireland)
Mallinckrodt(Ireland)
MSN Laboratories(India)
Ovid Therapeutics(U.S.)
SGPharma Pvt. Ltd.(India)
Teva Pharmaceutical Industries Ltd.(Israel)
Zydus Group(India)
Merz Therapeutics(U.S.)
Ionis Pharmaceuticals(U.S.)
Sun Pharmaceutical Industries Ltd.(India)
Dr. Reddy's Laboratories Ltd.(India)
Eisai Co., Ltd.(Japan)
결론과 제안
LSH
영문 목차
영문목차
Global Infantile Spasms Therapeutics Market size was valued at USD 140.0 million in 2023 and is poised to grow from USD 149.24 million in 2024 to USD 248.85 million by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).
Market insights indicate a rising global demand for infantile spasms therapeutics, driven by an increasing prevalence of the condition in both developed and developing regions. Enhanced awareness among pediatricians and significant investments in R&D are propelling revenue growth, while advancements in drug formulations and the expansion of pediatric neurology services improve access to these therapies. Innovative tools such as advanced EEG, MRI, and genetic sequencing are facilitating earlier diagnoses. Support from government healthcare programs and nonprofit organizations is further amplifying awareness and funding for rare pediatric neurological disorders. However, challenges such as high treatment costs, a scarcity of trained specialists, potential side effects of existing treatments, and underdiagnosis in less developed areas may hinder market sales in the future.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Infantile Spasms Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Infantile Spasms Therapeutics Market Segments Analysis
Global Infantile Spasms Therapeutics Market is segmented by Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Anticonvulsants, Corticosteroids and Others. Based on Type, the market is segmented into Vigabatrin, Adrenocorticotropic Hormone and Phase III. Based on Dosage, the market is segmented into Solid and Liquid. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Clinic, Hospital and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Infantile Spasms Therapeutics Market
The increasing awareness among the medical community regarding infantile spasms has significantly improved the speed of diagnosis and treatment. Pediatricians and general practitioners are now more knowledgeable about the condition's symptoms and the critical need for prompt intervention, resulting in quicker referrals to specialists for suspected cases. This heightened clinical awareness has accelerated therapeutic responses, minimizing long-term neurodevelopmental impairment and promoting a greater reliance on therapeutics designed for infantile spasms. Consequently, this trend is driving growth in the global market for infantile spasms therapeutics, as more healthcare providers prioritize timely and effective care for affected infants.
Restraints in the Global Infantile Spasms Therapeutics Market
The Global Infantile Spasms Therapeutics market faces notable challenges due to the substantial side effects associated with treatments such as ACTH and vigabatrin. Adverse effects including adrenal suppression, vision loss, and immune suppression often create hesitation among healthcare providers and parents regarding the initiation of therapy. This apprehension can result in premature discontinuation or outright avoidance of treatment, especially in borderline cases. Additionally, the lack of safer long-term alternative therapies exacerbates these concerns, impacting overall treatment compliance and limiting the market's growth potential. Hence, these factors represent a significant restraint within the sector.
Market Trends of the Global Infantile Spasms Therapeutics Market
The Global Infantile Spasms Therapeutics market is witnessing a significant shift towards precision medicine and genetic profiling, driven by advances in molecular diagnostics. This trend underscores the importance of personalized treatment strategies, with genetic testing and next-generation sequencing playing crucial roles in identifying the underlying causes of infantile spasms. As these technologies become more affordable and accessible, pharmaceutical companies are increasingly investing in mutation-targeted therapies, enhancing the effectiveness of treatments. This strategic focus on tailored approaches is expected to shape the future of the market, leading to improved patient outcomes and fostering innovation in therapeutic options for infantile spasms.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Global Infantile Spasms Therapeutics Market Size by Treatment & CAGR (2025-2032)
Market Overview
Anticonvulsants
Corticosteroids
Others
Global Infantile Spasms Therapeutics Market Size by Type & CAGR (2025-2032)
Market Overview
Vigabatrin
Adrenocorticotropic Hormone
Phase III
Global Infantile Spasms Therapeutics Market Size by Dosage & CAGR (2025-2032)
Market Overview
Solid
Liquid
Global Infantile Spasms Therapeutics Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Parenteral
Others
Global Infantile Spasms Therapeutics Market Size by End User & CAGR (2025-2032)
Market Overview
Clinic
Hospital
Others
Global Infantile Spasms Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Infantile Spasms Therapeutics Market Size & CAGR (2025-2032)
North America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
US
Canada
Europe (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Treatment, Type, Dosage, Route of Administration, End User, Distribution Channel)
